Cardioprotective potential of simvastatin in the hyperhomocysteinemic rat heart

Area of Science:

• Cardiovascular Science
• Pharmacology
• Biochemistry

Background:

• Hyperhomocysteinemia (Hhcy) is associated with increased cardiovascular risk and impaired cardiac function.
• Ischemia-reperfusion (I/R) injury is a major cause of myocardial damage.
• The cardioprotective effects of statins in Hhcy conditions require further investigation.

Purpose of the Study:

• To investigate the role of simvastatin in mitigating I/R-induced myocardial injury in hyperhomocysteinemic (Hhcy) rat hearts.
• To assess the impact of simvastatin on oxidative stress markers in Hhcy rat hearts subjected to I/R.
• To determine if simvastatin can restore abrogated cardioprotection in Hhcy.

Main Methods:

• Isolated Langendorff's perfused normal and Hhcy rat hearts were subjected to global ischemia followed by reperfusion.
• Myocardial damage was assessed by infarct size, and lactate dehydrogenase (LDH) and creatine kinase (CK-MB) release.
• Oxidative stress was evaluated by measuring lipid peroxidation and superoxide anion generation.

Main Results:

• I/R induced significant myocardial injury and oxidative stress in both normal and Hhcy rat hearts.
• Hhcy hearts exhibited exacerbated injury and higher oxidative stress compared to normal hearts.
• Simvastatin treatment (10 μMol) significantly reduced infarct size, LDH/CK levels, and oxidative stress in both normal and Hhcy hearts, indicating cardioprotection.

Conclusions:

• Simvastatin demonstrates significant cardioprotective effects against I/R injury in both normal and Hhcy rat hearts.
• The cardioprotection afforded by simvastatin is likely mediated by the reduction of oxidative stress.
• These findings suggest simvastatin's potential therapeutic value in managing cardiovascular complications associated with hyperhomocysteinemia.